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Sensory Neuronopathies or 
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INTRODUCTION
The different disorders characterized by a primary de-
generation of sensory neurons in dorsal root ganglia 
(DRG) are referred to as polyganglionopathies, ganglion-
opathies, ganglioneuritis, or simpler sensory neuronopathies 
(SNNs) (1–3). They represent a rare specific subgroup of 
peripheral nervous system diseases that should be dif-
ferentiated from polyneuropathies because they need 
specific investigations and treatments because of their 
frequent association with neoplastic or dysimmune 
disorders and with toxic agents and more rarely with 
genetic disorders (1,2,4).
In the late 1940s, Denny-Brown (1901–1981) recog-
nized the 2 most severe forms, those resulting from a 
remote effect of cancer (the paraneoplastic subtype) (5) 
and a hereditary subtype (6). During the last 40 years 
(see Refs (3,7) for historical reviews), it has been dem-
onstrated pathologically that DRG degeneration was 
associated with an inflammatory T-cell reaction in dif-
ferent disorders driven by a cell-mediated immune 
response such as in paraneoplastic SNN (8–10), HIV 
infection (11,12), Sjögren syndrome (SS), unclassified 
connective diseases, and rare idiopathic cases (13–19). 
That sensory neuron cell is the target of cisplatin toxic-
ity has also been recognized (20,21). Conversely, with 
vitamin B6 toxicity (22,23) or antidisialosyl antibodies 
(24), the demonstration of DRG involvement relies on 
animal models only.
Asbury (25) proposed that a non-length–dependent 
distribution of sensory loss and an almost pure elec-
trophysiological (EDX) sensory involvement are dis-
tinctive of SNN, the involvement of DRG sensory 
neurons causing degeneration of both their central and 
peripheral sensory projections. Although universally 
accepted, the Asbury criteria have not been validated 
until recently (26) (see the Common Pattern of SNN sec-
tion), and these have been used to understand why this 
distinct pathological process leads to the concomitant 
degeneration of short- and long-length axons, which 
is reflected in the proximodistal clinical presentation. 
However, as DRG cannot easily be explored, the clini-
cal diagnosis of these disorders may be difficult due to 
the presence of combined neurological manifestations, 
such as autonomic neuropathy, motor neuron disorder, 
limbic dysfunction, or cerebellar signs, and in some 
conditions, the DRG involvement is not the rule but 
may be associated with other forms of neuropathy, as 
exemplified in SS.
This chapter will therefore focus on the clinical 
presentation and mechanisms involved in acute and 
chronic SNN and describe the treatment strategies be-
fore discussing the differential diagnosis that include 
the dysimmune, the hereditary, and the infectious ataxic 
neuropathies.
GENERAL CLINICAL PRESENTATION
Onset and Rate of Evolution
SNN, particularly when paraneoplastic, toxic, or associ-
ated with SS, can have a subacute onset within a few days 
to several weeks. However, the course of SNN may also 
be indolent, such as in hereditary, idiopathic, or associ-
ated with unclassified connective diseases. The exten-
sion of the sensory loss may be limited and an absence 
of progression may be observed over several months or 
years, or conversely, the predominantly loss of deep sen-
sation may extend over all 4 limbs and may affect the 
face, tongue, chest, or abdomen, and patients may be-
come bedridden and die from complications of bed rest.
Clinical Manifestations
Patients typically show early loss of kinetic (motion) 
sense due to denervation of muscle spindles and joints, 
loss of vibration, denervation of receptors situated in 
the skin and periosteum, areflexia, together with vari-
ous combinations of positive and negative sensory and 
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painful symptoms that involve, sometimes asymmetri-
cally, both proximal and distal sites of the body, includ-
ing the trunk and the face. The upper limbs may be 
preferably involved, and the patient is unable to appre-
ciate the slight movements at the interphalangeal joints 
by passively moving 1 digit. As the pathological process 
becomes more extensive, loss of such recognition for 
the hand or entire extremity develops, with abnormal 
finger-to-nose test. Some patients develop pseudoathe-
toid (waver) movements in the hands or fingers when 
asked to hold hands outstretched while eyes are closed 
(figure 20.1). In the foot, the perceptions of motion, po-
sition, and vibration may be equally affected, with an 
abnormal heel-to-knee-to-toe test and an early Romberg 
sign when the patient is able to stand with his feet to-
gether while his eyes are open but sways or falls when 
they are closed. The gait may be unsteady, particularly 
when asked to walk tandem by placing one heel directly 
in front of the opposite toes. These manifestations have 
led to the designation of “ataxic neuropathies,” a mis-
leading term because it could also include demyelinat-
ing neuropathies. In some patients, neuropathic pain and 
predominantly small-fiber sensory loss involve proxi-
mal regions of the limbs, face, and trunk, either sparing 
the acral extremities or with simultaneous involvement 
of distal and proximal areas in a non-length–dependent 
pattern. This pattern suggests that the pathology may 
be localized to small-fiber neurons in the DRG and is 
similar to what had been described clinically and patho-
logically in patients with fabry disease (27).
Common Pattern of SNN
A recent study has proposed diagnostic criteria for SNN 
(26). logistic regression was used to test sets of clinical, 
EDX, cerebrospinal fluid (CSf) parameters, and parane-
oplastic antibody results to retrospectively discriminate 
patients with SNN and distal sensory neuropathies. The 
optimum set of criteria for SNN was tested prospectively 
in 37 patients with sensory neuropathies and accurately 
identified 81.6% of them as SNN. This study proposes to 
use a validated score to recognize SNN independently 
of the underlying cause (Table 20.1).
GENERAL INVESTIGATIONS
Electrophysiological Testings
The most common abnormality of nerve conduction in 
SNN is absent or low-amplitude sensory action poten-
tials (SAPs) with normal or relatively preserved conduc-
tion velocities in the clinically involved extremity. Most 
published series report a widespread decrease in SAPs 
amplitudes, which involved both upper and lower limb 
nerves, even in patients with asymmetrical or patchy 
clinical presentation (28–30), arguing for a need of sys-
tematic and bilateral recording of the median, ulnar, 
radial, superficial peroneal, and sural sensory nerves. 
In the recently published SNN score (26) (Table 20.1), at 
least 1 SAP should be absent or 3 SAPs should have an 
amplitude <30% of the lower limit of normal in the upper 
limbs, and fewer than 2 nerves may have abnormal motor 
nerve conduction studies in the lower limbs motor (ab-
normalities significantly more frequent in patients with 
paraneoplastic SNN). Nerve conduction studies should 
not reveal the cardinal features of demyelination as ob-
served in neuropathies associated with gammopathy (46) 
or in chronic inflammatory demyelinating polyneuropa-
thy (47) (Table 20.2). Somatosensory-evoked potentials 
(26,28) and the trigeminal blink reflex (31) can be useful 
to demonstrate abnormal proximal sensory conduction.
Imaging Techniques
Increased T2-weighted magnetic resonance imaging 
(MRI) signal changes were detected in the posterior col-
umns of 15 patients with chronic SNN (28) and in 9 of 
the 12 examined patients with SS SNN in T2*-weighted 
MRI (19). The extent of dorsal-column high-intensity 
T2* signal was correlated with the distribution and in-
tensity of sensory involvement and sensory ataxia, in-
dicating the presence of central rami involvement due 
to sensory ganglion neuron damage (19,32). In a more 
recently published study, the percentage of abnormali-
ties was lower: in the 22 patients who underwent spinal 
cord MRI (4 cisplatin, 2 paraneoplastic, and 16 likely 
SNN), an abnormal high signal of the posterior column 
was observed in only 1 of them (26).
FIGURE 20.1 Pseudoathetosis of the right hand in a 56-year-old patient with inflammatory ganglionitis related to a 
mixed connective tissue disease. She complained of chronic unpleasant sensations in all fingers (digits I and II > III, IV, 
and V ), with a mixed impression of tingling, burning, and dysesthesia, and with an inability to know where her right hand 
was in the dark. On examination, the deficits were strictly localized in the right upper extremity, with areflexia, loss of 
all sensations, and with a predominant loss of proprioception of the fingers. Pseudoathetosis, shown in this series of 
photographs, is characterized by the presence of undulating and writhing movements of the right fingers when the eyes 
are closed. With permission from Elsevier Masson France (4).
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Blood and Biological Parameters
Erythrocyte sedimentation and other systemic markers 
are usually normal. Serological markers (rheumatoid 
factor, antinuclear antibodies) may suggest specific con-
nective tissue disorders.
CSf examination is usually normal or demonstrates a 
slightly elevated protein value (18,19,29,33). In one study 
in which CSf was examined in 48 patients (3 cisplatin, 24 
paraneoplastic, and 21 likely SNN), it was significantly 
abnormal in patients with paraneoplastic SNN with a 
TABLE 20.1 Diagnosis of SNN
Diagnosis of SNN is considered as “possible” based on examination and on results of the electrodiagnostic 
studies, “probable” as related to the biological workup and imaging data, and “definite” if DRG degeneration is 
pathologically proven, although DRG biopsy is not recommended (26).
A.  In a patient with a clinically pure sensory neuropathy, a diagnosis of SNN is considered as possible  
if score >6.5
yes Points
a. Ataxia in the lower or upper limbs at onset or full development ¨ +3.1
b. Asymmetrical distribution of sensory loss at onset or full development ¨ +1.7
c. Sensory loss not restricted to the lower limbs at full development ¨ +2.0
d.  At least 1 SAP absent or 3 SAP <30% of the lower limit of normal in the upper limbs, not 
explained by entrapment neuropathy
¨ +2.8
e. fewer than 2 nerves with abnormal motor nerve conduction studies in the lower limbs ¨ +3.1
Total
B. A diagnosis of SNN is probable if the patient’s score is >6.5 and if
1.  The initial workup does not show biological perturbations or ENMG (electroneuromyography) findings 
excluding SNN; or 
2.  The patient has 1 of the following disorders: onconeural antibodies or a cancer within 5 years (34), cisplatin 
treatment, SS (74); or
3. MRI shows high signal in the posterior column of the spinal cord.
C.  A diagnosis of SNN is definite if DRG degeneration is pathologically demonstrated although DRG biopsy is not 
recommended.
Q1
TABLE 20.2 Differential Diagnosis of Sensory Neuronopathy
Neuropathy Examples Remarks
Infectious ataxic 
neuropathies
Syphilis, diphtheria, human T-cell 
lymphotropic virus, HIV
Appropriate laboratory testing needed
Tropical ataxic 
neuropathy
Strachan syndrome, Cuba epidemic 
neuropathy, konzo epidemic  
paralytic disease
Appropriate laboratory testing needed
Neuropathy associated 
with gammopathy
Neuropathy associated with 
osteosclerotic myeloma, with 
monoclonal gammopathies of 
undetermined significance and with 
Waldenström macroglobulinemia, 
PoEMS syndrome
Workup for underlying cancer and appropriate 
laboratory testing needed, see EfNS/PNS 
guidelines (118)
Chronic inflammatory 
demyelinating 
polyneuropathy
– Progressive polyradiculoneuropathy with clinical 
course for >2 mo, see EfNS/PNS guidelines 
(119)
Inherited neuropathy friedreich ataxia, ataxia with vitamin 
E deficiency, abetalipoproteinemia, 
SANDo with mutation of the POLG 
gene, combined SNN, and motor 
neuron disorders
family history often negative, DNA analysis 
needed
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more frequent raised protein level and oligoclonal pat-
tern (26). Pleocytosis suggests infiltrative or infectious 
conditions, particularly HIV infection, but is reported in 
80% of limbic encephalitis, potentially associated with 
paraneoplastic SNN (34).
A number of molecules that are principally localized to 
the neuronal compartment of the peripheral nerve have 
been identified as relevant to the pathogenesis of autoim-
mune neuropathy (7). These antigens include the parane-
oplastic antigens Hu, CV2, and amphiphysin, which are 
associated with the development of paraneoplastic SNN 
and the antidisialosyl gangliosides antibodies.
In the paraneoplastic SNN, the origin of the immune 
response is presumed to be against the tumor cells in 
which the neural antigens are inappropriately expressed. 
When the antigens are expressed on the plasma mem-
brane, the immunopathology is primarily dependent 
on antibody-mediated processes. However, in those 
paraneoplastic syndromes involving an intracellular an-
tigen, the mechanism of pathogenesis is not clear, but 
there is evidence for the involvement of cytotoxic T cells. 
In the mid-1980s, investigators described antibodies in 
the serum and CSf of patients with small-cell lung car-
cinoma (SClC) and SNN that were subsequently shown 
to recognize specific antigens expressed on neural cells 
and the underlying tumor (35). A number of such ner-
vous system–specific autoantibodies have now been 
described in a variety of paraneoplastic neurological dis-
eases (36). Among the antibodies directed against neural 
antigens in serum and CSf, the most characteristic being 
antibodies directed against neuronal nuclear antigens, 
anti-Hu or ANNA-1 (both nomenclature remain in cur-
rent use). Among 979 patients with paraneoplastic neu-
rological syndrome recruited from 20 European centers 
(36), the onconeural antibody profile confirmed Hu as 
the most frequent antibody (38.8%), followed by yo or 
anti-Purkinje cell antibodies (13.4%). All other antibodies 
had frequencies below 10.0%. The antibody types were 
within the spectrum for onconeural antibodies and in 
association with paraneoplastic neurological syndrome 
have significant diagnostic value for an underlying can-
cer, with an association between anti-Hu antibodies, the 
subacute SNN and SClC, and between antiamphiphysin 
and anti-CV2 and paraneoplastic SNN and sensorimo-
tor neuropathy and SClC, breast, colon, prostate, thy-
moma, and other cancers for the peripheral neuropathies 
(7,36).
In 1985, circulating IgM antibodies reacting with 
NeuAc (a2-8) NeuAc (a2-3) Gal-configured disialosyl 
gangliosides (including GD1b, GD3, GT1b, and GQ1b) 
were first described in a patient with chronic sensory 
neuropathy (37). Since then, neuropathies associated 
with IgM antibodies against disialosyl residues have 
been defined as either sensory ataxic neuropathy associ-
ated with anti-GD1b IgM antibody (38), or chronic sen-
sory ataxic neuropathy associated with antidisialosyl 
IgM antibodies, a so called chronic ataxic neuropathy in-
Q2
volving ophthalmoplegia, IgM paraprotein, cold agglu-
tinins, and disialosyl antibodies (CANoMAD) (39). The 
most prominent feature of these neuropathies is sensory 
ataxia with relatively well-preserved muscle strength 
and small-fiber sensation. An immunohistochemical 
study showed localization of GD1b in the neurons of 
human DRG (40,41). Moreover, experimental sensory 
neuropathy is induced by sensitization with monospe-
cific GD1b (41). GD1b, therefore, is recognized as a puta-
tive target molecule for serum antibodies. 
Biopsies
Morphological studies have focused on the sural nerve, 
with only a few reports of DRGs (8–10,13–21). In sural 
nerve biopsy and autopsy material, the characteristic 
features are a marked fiber loss, active axonal degen-
eration, and cellular infiltrates around epineurial blood 
vessels. There may be fascicle-to-fascicle variation in the 
degree of fiber loss or axonal degeneration, and necro-
tizing vasculitis may also be seen. We observed similar 
findings (figure 20.2). The characteristic findings in the 
DRGs are inflammation and neuron loss with formation 
of residual nodules of Nageotte (clusters of supporting 
cells). The majority of inflammatory cells are T lympho-
cytes with scattered macrophages (figure 20.3). Because 
of the risks involved, spinal ganglion biopsy is rarely 
performed and should be restricted to only a select 
group of patients (13).
DISORDERS ASSOCIATED WITH SNN
Paraneoplastic Subacute SNN
Introduction and Epidemiological Data
Paraneoplastic neuropathies may occur in isolation 
such as the disorder described in 1948 by Denny-Brown 
(5), but more commonly, there is a complex syndrome 
with a concomitant involvement of both the central 
and the peripheral nervous systems, called paraneo-
plastic encephalomyelitis (PEM) with subacute SNN 
or PEM/SNN (1,2,7). There is abundant evidence that 
the paraneoplastic SNNs represent disordered autoim-
munity, the exact pathogenic mechanisms are yet to be 
elucidated (7).
In a clinicopathological review of 69 patients with 
paraneoplastic neurological disease, Henson and urich 
(42) recognized that SNN and encephalomyelitis fre-
quently developed together, particularly in associa-
tion with SClC. With the recognition and detection of 
anti-Hu antibodies (see the General Investigations sec-
tion) in the serum of patients with PEM or SNN it was 
observed that these were different manifestations of the 
same underlying disease process. These anti-Hu anti-
bodies react with a family of protein antigens of 35 to 
40 kDa present in neurons and some tumors, especially 
SClC. The binding of an antibody to a particular neural 
antigen on the exposed cellular structure of a fixed brain 
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section does not indicate the mode of pathogenicity of 
the neurological syndrome; this varies. for example, 
anti-Hu is directed against nuclear antigens (a family of 
RNA binding proteins normally expressed in the ner-
vous system); presumably, these ectopically expressed 
nuclear antigens become externalized during the anti-
tumor immune response. Although high-titer IgG an-
tibodies against Hu and related antigens occur in the 
circulation and CSf, it has not been possible to demon-
strate any cytopathic effect of this antibody on neurons, 
although the antibody can be detected in the nuclei of 
the exposed cells (43); for example, passive transfer of 
anti-Hu–containing IgG into animals does not induce 
disease (44). In anti-Hu syndromes the neuropathology 
is thought to be cell mediated (45) and the antibody is 
merely an immunological accompaniment.
SNN is a rare paraneoplastic complication. In a pro-
spective study of 150 consecutive patients with SClC, 
only 1 patient was found with SNN and 2 patients had 
the lambert-Eaton myasthenic syndrome (lEMS) (46). 
In another study of 203 patients, 5 had peripheral neu-
ropathy with no cause and 5 others manifested anti-
body-mediated paraneoplastic neurological syndromes 
(lEMS, limbic encephalitis, cerebellar degeneration) (47). 
There is less information regarding the incidence of neu-
ropathy in breast and gynecological malignancies (48). 
The prevalence of malignancy associated neuropathy in 
patients with peripheral neuropathy is not accurately 
known. from 422 consecutive patients with peripheral 
neuropathy, 26 were analyzed who concomitantly had 
carcinoma but no tumorous infiltration, drug toxicity, 
or cachexia (49). Twenty-one (5%) of these patients had 
either antineuronal antibodies or a short interval be-
tween onset of neuropathy and diagnosis of malignancy 
or a clinical course consistent with a paraneoplastic 
etiology. The remaining 5 patients had a long inter-
val between onset of neuropathy and malignancy and 
a chronic progressive course suggesting a coincidental 
association. 
Clinical Manifestations
They are well characterized (5,7,50–52). Symptoms in-
clude combination of paresthesias, sensory loss, and 
dysesthesia; pain is often severe. At onset, the distribu-
tion is frequently multifocal or asymmetrical and can be 
confused with mononeuritis multiplex. The upper limbs 
are usually affected first. Sensory loss, with a predomi-
nantly loss of proprioception, extends over all 4 limbs 
and may affect the face, chest, or abdomen. This results 
in lower-limb ataxia and an unsteady gait, and in the up-
per limbs, some patients develop pseudoathetoid move-
ments in the hands (see the previous General Clinical 
Control
n
16
14
12
10
8
6
4
2
2 4 6 8 10 12 µm
Control (n=124)
Patient (n=229)
F= 30000 µm2
A C
B
FIGURE 20.2 A, Sural nerve biopsy from a 61-year-old woman with SS and sensory neuronopathy with gait ataxia, 
demonstrating loss of nerve fibers. B, Age-matched control patient (Thionin blue, original magnification ´600). The 
histogram shows the loss of large and small nerve fibers. C, Same case as in A, with lymphocytic epineural blood vessel 
wall infiltration without necrosis, showing the presence of vasculitis (hematoxylin and eosin, original magnification ×400). 
With permission from John Wiley & Sons (1).
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Presentation section). loss of taste and hearing may be 
seen (53). Tendon reflexes are reduced or absent. Strength 
is usually preserved unless there is some degree of mo-
tor axon loss (54).
The most frequent manifestation of PEM/SNN is 
SNN, occurring in 74% of cases. However, it is predomi-
nant in only 50% to 60% of patients and clinically pure 
in only 24% (34,54). About 50% to 75% of the patients 
develop more widespread neurological involvement, 
including limbic encephalitis, encephalomyelitis, med-
ullary syndrome, with or without pontine or bulbar 
manifestations, dysautonomia, cerebellar degeneration, 
and lEMS (51,54–56). In one large series of 200 patients 
with anti-Hu antibodies, neurological dysfunction was 
confined to 1 area of the nervous system in 30% patients 
(SNN, 48; cerebellar ataxia, 4; limbic encephalitis, 4; 
brainstem encephalitis, 2; intestinal pseudo-obstruction, 
1; parietal encephalitis, 1) (54). The other patients had 
evidence of multifocal involvement. A predominant 
neurological syndrome was identified in 118 of them, 
whereas in 22 more than 1 syndrome predominated 
during the clinical evolution.
The onset is usually subacute (a few days to several 
weeks) and rapidly progressive, although occasional 
patients have an indolent course with slow progression 
over months. usually, paraneoplastic SNN is a severe 
disease. Many patients become bedridden and die from 
complications of bed rest or inactivity rather than from 
cancer progression. However, a subset undergoes an 
indolent course, with a very limited extension of the 
sensory loss and absence of progression after several 
months or years (57). The onset of neuropathy precedes 
diagnosis of cancer in the majority of cases (77%–88%), 
with a median interval from onset of symptom to tumor 
diagnosis 3.5 to 6 months (range, 1–47 months) depend-
ing on the series (51,54,55,57). like other paraneoplastic 
syndromes, SNN usually presents in middle or older 
age. Age older than 60 years, neurological disability 
score at diagnosis, more than 1 area of the nervous sys-
tem affected, and absence of treatment predict survival 
and neurological outcome (54).
Diagnosis
The classical paraneoplastic SNN should be considered 
if all the following criteria are present (34): subacute 
onset with a Rankin score of at least 3 before 12 weeks 
of evolution, onset of numbness, and often pain, marked 
asymmetry of symptoms at onset, involvement of the 
arms, proprioceptive loss in the areas affected, and EDX 
studies that show marked, but not restricted, involve-
ment of the sensory fibers with absent SAPs in at least 1 
of the nerves studied. A recent study has advanced di-
agnostic criteria for possible, probable, or definite SNN 
using a composite score (Table 20.1) (26).
Q3
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FIGURE 20.3 Pathological examination of a lumbar DRG from a patient with sensory neuronopathy and anti-Hu antibodies 
who died 14 months after the onset of SSN. A, There is evidence of massive mononuclear cell infiltration with signs of 
degenerating neurons (indicated by asterisks) (hematoxylin and eosin, original magnification X20). (B) Presence of cytotoxic 
CD8 T cells (indicated by arrows) surrounding a neuron (N) (immunostaining, original magnification X40). C, Interstitial 
distribution of CD4 helper T cells and macrophages (indicated by arrows) (immunostaining, original magnification X40). 
D, Direct neuronal (N) involvement is shown by the release of perforin granules by a cytotoxic T cell (indicated by arrows) 
in close contact with a sensory neuron (immunostaining, original magnification X100). E, Expression of CD45RO by the 
inflammatory cells indicates that they are of the memory subset (immunostaining, original magnification X40). F, Enhanced 
expression of MHC class I molecules by the satellite cells of a sensory neuron (N), favoring T-cell antigen recognition 
(immunostaining, original magnification X40). Reproduced with permission from John Wiley & Sons (1).
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Several large series have found that 85% of patients 
with PEM/SNN and high titers of anti-Hu antibodies 
have detectable underlying neoplasm, most commonly 
SClC. However, a wide variety of cancers, including 
breast, prostate, ovarian, endometrial, and undefined ad-
enocarcinomas, neuroblastomas, and germ cell t umors, 
have been reported (54,55,57,58). Tumor diagnosis may 
be challenging, when the tumor is restricted to the medi-
astinal lymph nodes (59). When conventional radiological 
methods are negative, whole-body [18f]fluorodeoxyglu-
cose positron emission tomography (18fDG-PET) is rec-
ommended (59,60). This has a high sensitivity but is not 
specific, as inflammatory tissues can take up the tracer. In 
15 patients with a paraneoplastic neurological syndrome 
and anti-Hu antibodies, radiological methods led to the 
diagnosis of cancer in 12 patients but not in the other 
3, whereas 18fDG-PET showed abnormal uptake in the 
mediastinum in all 15 patients, in accordance with the 
expected location of the malignancy (59). laboratory in-
vestigations and electrodiagnostic findings have already 
been described (see the Blood and Biological Parameters 
and Electrophysiological Testings section). Detection of 
anti-Hu antibodies is of great value in the diagnosis of 
cancer. The estimated specificity is 99%, but the sensi-
tivity is only 82%, so the absence of anti-Hu antibodies 
in patients suspected of having SNN does not exclude 
an underlying cancer (61). This finding highlights the 
importance of the Graus criterion (34) that paraneo-
plastic syndrome may be diagnosed in the absence of 
a malignant neoplasm or onconeural antibodies when 
the patient profile fulfills the other criteria for classic 
paraneoplastic syndrome. There is a lack of correlation 
between the Hu-Ab titers and the tumor evolution prob-
ably reflecting that Hu-Abs are a surrogate marker of 
the evolving immune response (62). Antibodies against 
the synaptic vesicle protein amphiphysin (described in 
paraneoplastic stiff-man syndrome and breast cancer) 
and against CV2 (associated with cerebellar degenera-
tion, uveitis, and peripheral neuropathy with a variety 
of cancers) have subsequently been demonstrated to be 
rarely associated with SNN, with and without anti-Hu 
antibodies (36).
The pathological lesions in SNN have long been known 
in DRGs and in sural nerve (see the previous Biopsies 
section) (8–10). In DRGs, they consist of mononuclear cell 
infiltrates surrounding sensory neurons undergoing 
degeneration. ultimately, the lost neurons are replaced 
by a proliferation of satellite cells, and presence of in-
traneuronal IgG deposits, anti-Hu antibodies cannot be 
demonstrated anymore from the lesions. Currently, T 
cells are thought to be mainly responsible for the dis-
ease. Although CD4 helper T cells are found around 
vessels and between sensory neurons, CD8 cytotoxic T 
cells are situated mainly around neurons and sometimes 
penetrate the capsule of satellite cells to come in close 
contact with sensory neurons. Some of these lympho-
cytes express the cytotoxicity-associated proteins, perfo-
rin, and TIA-1 (figure 20.3). Although an autoimmune 
pathogenesis for PEM/SNN is indicated by the presence 
of specific anti-Hu antibodies in serum and CSf, lym-
phocytic pleocytosis and oligoclonal bands in CSf, and 
inflammatory infiltrates in affected areas of the nervous 
system, the exact pathogenic mechanisms remain un-
certain. The central theory of pathogenesis is however 
based on the presence of specific anti-Hu antibodies that 
react with an underlying tumor and on the concept of 
molecular mimicry whereby expression of neuronal an-
tigens by the tumor leads to a breakdown of immune 
tolerance and subsequent immune-mediated neuronal 
damage (7).
Treatment
This is largely disappointing, and antitumor therapy 
seems to be more effective than immunomodulatory 
therapy. large series failed to demonstrate a clear ben-
efit of intravenous immunoglobulin (IVIg), steroids, 
plasma exchange, or cyclophosphamide, either alone 
or in combination (55,57,58,63). There are uncontrolled 
studies that report stabilization of treated patients with 
IVIg (64,65), combined immunosuppressive treatment 
(66,67), rituximab treatment (68), but its significance is 
difficult to assess given the tendency of the SNN to pla-
teau in untreated cases and the occurrence of occasional 
spontaneous remission (57). A large series of PEM/SNN 
concluded that a trial with immunotherapy should be 
considered in PEM patients when antineoplastic treat-
ment is not possible because a tumor is not found or 
when PEM/SNN appears during or after tumor treat-
ment (54). Based on this and on clinical observations 
that T-cell autoimmune diseases regress during preg-
nancy, 15 patients with anti-Hu antibodies were treated 
in a prospective, uncontrolled, and unblinded trial with 
10 000 Iu daily of human chorionic gonadotropin ad-
ministered by intramuscular injection during 12 weeks. 
Seven (47%) patients improved or stabilized (69). The 
authors conclude that human chorionic gonadotropin 
may have immunomodulatory activity and may mod-
ify the course of Hu-paraneoplastic syndromes. The 
results of antitumor therapy are more promising. In a 
large series, treatment of the tumor was a predictor of 
improvement or stabilization of the neurological disor-
der (51,54,57,63), suggesting that early diagnosis of the 
cancer gives the best chance of helping the neurological 
disorder before it becomes too devastating.
Dysimmune SNN
Introduction
The dysimmune SNNs are uncommon but represent the 
most frequently encountered cause of SNN. They include 
disorders of the DRG thought to be immune mediated, 
excluding cases associated with malignancy and toxins 
affecting primary sensory neurons. In 1968, 2 patients 
were reported with acute pure sensory neuropathy not 
associated with malignancy with multifocal radicular 
sensory loss with selective loss of large-diameter sural 
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nerve fibers suggested DRG as locus of disease (70). Ad-
ditional case reports confirmed this distinct clinical entity 
(33,71,72). In the 1990s, other findings such as the acute or 
subacute, often focal, onset in the absence of inflamma-
tion in distal peripheral nerve suggested an immune me-
diated or vascular process at the level of DRG (18,29,30). 
Since then, several authors have reported detailed clini-
cal, electrodiagnostic, biological, and pathological data 
for cases with acute, subacute, or chronic SNN most of-
ten associated with SS (see reviews by kuntzer et al (1), 
Sghirlanzoni et al (2), and Smith (3)).
Clinical Manifestations
In dysimmune SNNs, there is a large variation in clini-
cal presentation, with a mixture of ataxia and pain 
syndrome (see the General Clinical Presentation sec-
tion), with sensory disturbances often unilateral, strik-
ingly asymmetric, at times predominantly in the upper 
limbs but may also initially involve the trunk, face, or 
lower limbs. These signs may be associated with auto-
nomic signs, such as Adie pupil, anhidrosis, postural 
hypotension, areflexia with normal strength. The course 
ranges from an abrupt to an indolent progression over 
several years. Although symptoms and signs are asym-
metric at onset, they become symmetric as the disease 
becomes generalized (29,30). The clinical manifestations 
of neuropathy preceded the development of an isolated 
sicca complex (keratoconjunctivits sicca and xerosto-
mia) or laboratory findings consistent with SS in most 
p atients. Thus, in most patients, neuropathy developed 
first and then the diagnosis of SS may be made years 
later (18,19,73). This chronological sequence is true for 
all forms of neuropathy but is more characteristic in the 
SNN forms. Extraneural symptoms, such as pancreatitis 
and interstitial pneumonia, also can precede the clini-
cal manifestations of SS. Peripheral neuropathy is the 
presenting problem in most patients, and SS-associated 
neuropathy has been shown to manifest as a variety of 
forms: in a study with 92 patients (19), 36 had SNN, 18 
painful sensory neuropathy without sensory ataxia, 11 
multiple mononeuropathy, 5 multiple cranial neuropa-
thy, 15 trigeminal neuropathy, 3 autonomic neuropathy, 
and 4 radiculoneuropathy based on the predominant 
neuropathic symptoms. Acute or subacute onset was 
seen more frequently in multiple mononeuropathy and 
multiple cranial neuropathy, whereas chronic progres-
sion was predominant in other forms of neuropathy.
Abnormal pupils and orthostatic hypotension were 
particularly frequent in sensory ataxic, painful, trigemi-
nal, and autonomic neuropathy. SNN frequently had 
painful features, autonomic symptoms and trigeminal 
nerve involvement. Painful sensory neuropathy also 
had autonomic and trigeminal nerve involvement, as 
well as sensory ataxic features.
Diagnosis With Special Interest on SS
These observations strongly suggest that neural tissues, 
particularly DRG cells and probably autonomic gan-
glion cells, are the primary targets in SS in addition to 
the salivary and lacrimal glands, and visceral organs 
including the pancreas, lung, and thyroid. A revised 
version of the European criteria has been proposed by 
an American-European Consensus Group (74) based 
on sicca symptoms, ocular signs, objective evidence of 
salivary gland involvement, and presence in the serum 
of autoantibodies to Ro (SSA) or la (SSB) antigens. 
The broad heterogeneity in the clinical and analytical 
features of patients with primary SS observed in some 
recent study (75) shows that our understanding of this 
systemic autoimmune disease is still evolving and that 
the different criteria used for the diagnosis of primary 
SS lead to different visions of the disease. The 2002 cri-
teria, in which anti-Ro/la antibodies and/or positive 
salivary gland biopsy are mandatory, principally clas-
sify patients with the most pronounced extraglandular 
and immunological expression. This subset of patients 
is easily diagnosed using these criteria, whereas patients 
with a predominantly sicca-limited disease, especially 
males, the elderly, and immunonegative patients, and 
patients with other manifestations not included in this 
classification criteria such as arthralgia, cytopenia, pa-
rotid enlargement, and Raynaud phenomenon are ex-
cluded. The 2002 criteria do not cover the broad clinical 
and immunological heterogeneity of primary SS, and 
primary SS should be considered as a systemic autoim-
mune disease that can express in many guises beyond 
sicca involvement.
Pathological data suggest an immune disorder di-
rected against neural elements, with involvement of 
large and small DRG cells with retrograde axonopathy, 
as described in many cases with electrodiagnostic studies 
(undetectable SAPs) or on nerve biopsies (figure 20.2). 
The events that lead to the autoimmune response and 
the underlying cause of SS remain enigmatic; however, 
lymphocytic disturbances, including ectopic germinal 
center formation, and aberrations of cellular signaling, 
play a significant role in this disorder, together with an 
underlying genetic predisposition that may vary be-
tween populations and additional factors priming or 
triggering the syndrome, such as hormonal influences, 
environmental factors, and infectious agents (76). labo-
ratory and clinical evidence suggest that proinflamma-
tory cytokines, particularly tumor necrosis factor (TNf) 
a, may also play a role.
Treatment
SS without extraglandular manifestations is a relatively 
benign entity, and treatment is supportive and primar-
ily directed against sicca complaints (77). The traditional 
antirheumatic agents show limited efficacy in the sys-
temic process and use of systemic TNf-a inhibitors has 
been very disappointing. B-cell–depleting treatments 
and other newer biologic therapies appear more promis-
ing. Specific treatment of the neuropathy depends on the 
pathogenesis of nerve involvement. In SNN, response 
to treatment has been disappointing in most patients. 
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Some patients improve after plasma exchange. Chen et 
al. (78) reported dramatic and sustained improvement 
in 2 of 4 patients with SNN secondary to SS after 5 to 9 
sessions of plasma exchange, with no detectable benefit 
in the other 2 patients, and suggested early treatment 
with plasma exchange. Also IVIg has been reported to 
be beneficial in longstanding SNN (79–81). In one study, 
IVIg was given to 5 patients with severe disabilities for 
an average of 12 years. four patients showed remark-
able improvement, 2 of whom responded after the first 
course (79), but controlled trials are lacking. Intramus-
cular interferon a recently demonstrated benefit in cases 
of sensory ataxic and sensorimotor neuropathy, with 
additional improvement in sicca symptoms, antibody 
titers, and salivary gland histology (82). Infliximab, al-
though ineffective for uncomplicated SS, was of benefit 
in a case of severe sensory neuropathy (83), indicating 
that anti–TNf-a therapy may have a role in subgroups 
of patients with severe disease. In a case of SS-associated 
IVIg-dependent ataxic neuropathy, rituximab adminis-
tration demonstrated a marked IVIg-sparing effect not 
observed in patients with other assumed antibody-
 mediated neuropathies (84). Based on the limited num-
ber of patients treated, there may be marked differences 
in the rates of favorable therapeutic response among the 
neuropathic forms, reflecting major differences in the 
causes of neuropathy. Prednisone is likely a good candi-
date for multiple mononeuropathy and multiple cranial 
neuropathy, and favorable improvement may be seen in 
the painful dysesthesias of the painful sensory neuropa-
thy and radiculoneuropathy forms with IVIg therapy. 
Although these symptomatic therapeutic responses 
were seen in certain patients, overall progression of the 
neuropathic symptoms as well as of SS syndrome itself 
occurred (19).
Autoimmune Ataxic Syndromes
Acute Sensory Ataxic Neuropathy
There is a clinical spectrum of autoimmune acute ataxic 
syndromes, ranging from sensory ataxic Guillain-Barré 
syndrome (GBS) to ataxic syndromes in which limb 
weakness is absent, such as fisher syndrome (fS) and 
Bickerstaff brainstem encephalitis (BBE) (85). Based on 
fisher and Bickerstaff’s findings, “progressive, rela-
tively symmetric external ophthalmoplegia, and ataxia 
by 4 weeks” are the clinical features necessary for the 
diagnoses of both BBE and fS (86). Although “hypore-
flexia or areflexia” and clear consciousness are required 
for the diagnosis of fS, “impaired consciousness” is re-
quired for that of BBE. Hyporeflexia or areflexia is not an 
exclusion criterion for the diagnosis of BBE because half 
of the original patients had hyporeflexia or areflexia.
Studies published in the 1990s showed that serum 
anti-GQ1b IgG antibody levels are frequently elevated 
in patients with fS or BBE. In a large published series of 
581 patients (86), anti-GQ1b IgG antibodies were posi-
tive in 68% of BBE patients and in 83% of fS. The pres-
ence of common antecedent infectious agents such as 
Campylobacter jejuni and Haemophilus influenzae in both 
conditions supports the hypothesis that BBE and fS 
have similar etiologies, as is the case for GBS and fS. 
Muscle spindles, proprioceptive transducers within the 
muscles, are an integral part of the g-reflex loop. They 
contain specialized muscle fibers that have motor inner-
vation and are enriched by a sensory ending. The neural 
components and intrafusal muscle fibers of these spin-
dles may be important targets in fS patients because 
they are labeled by a monoclonal antibody against b- 
series gangliosides, including GQ1b, in mice and rats (87) 
and a monoclonal anti-GQ1b/GT1a antibody in humans 
(88). The latter staining pattern suggests that the group 
1a afferents in muscle spindles contain GQ1b. Human 
immunohistochemical studies using a monoclonal anti-
GQ1b/GT1a antibody have shown the existence of some 
large neurons in DRG, which could be group 1a neurons 
(89). GQ1b at the NMJs of oculomotor muscles and on 
muscle spindles may be targets and produce the charac-
teristic combination of fS clinical symptoms. The prob-
able sequence of events in the pathogenesis of BBE and 
fS therefore is as follows: Infection by a microorganism 
bearing the GQ1b epitope induces production of anti-
GQ1b IgG antibodies in certain patients. The anti-GQ1b 
antibodies bind to GQ1b expressed on the oculomotor 
nerves and muscle spindles, inducing fS. In some cases, 
anti-GQ1b antibodies also enter the brainstem in areas 
where the BBB is deficient (eg, the area postrema) and 
binds to GQ1b, which may be expressed on the brain-
stem reticular formation, inducing BBE. The finding 
that both conditions have autoantibodies in common 
suggested that the autoimmune mechanisms are the 
same in both and are not distinct conditions. Common 
autoantibodies, antecedent infections, and neuroimag-
ing and neurophysiological results from a large study 
offer conclusive evidence that these conditions form a 
continuous spectrum with variable central and periph-
eral nervous system involvement. A new eponymic ter-
minology “fisher-Bickerstaff syndrome” may be helpful 
for nosology (85). Because randomized controlled trials 
have established the efficacy of plasma exchange and 
IVIg for GBS, either treatment should be given to pa-
tients with fS/GBS or BBE/GBS overlap. Their efficacy 
for treating fisher-Bickerstaff syndrome, however, has 
yet to be shown as there have been no randomized con-
trolled trials (90).
Chronic Sensory Ataxic Neuropathy Associated With 
Antidisialosyl Ganglioside Antibodies
In contrast to the acute fS associated with IgG autoan-
tibodies against disialosyl epitopes, including GD1b 
and GQ1b, monoclonal IgM antidisialosyl ganglioside 
antibodies are typically associated with chronic ataxic 
neuropathy with ophthalmoplegia, IgM paraprotein, 
cold agglutinins, and anti-GD1b disialosyl antibodies 
(CANoMAD) (39). In this syndrome, the IgMs react 
with the disialosyl epitope shared by gangliosides GD1b, 
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GQ1b, GT1c, and GD3(also see the General Investiga-
tions section). This form of sensory ataxic neuropathy, 
occasionally with ophthalmoplegia or bulbar signs, af-
fects large sensory fibers and is characterized by distal 
paresthesias, numbness, prominent ataxia, areflexia, and 
mild or no limb weakness. Experimental sensitization 
with GD1b cause ataxic sensory neuropathy in rabbits 
and humans due to antibody-mediated damage to the 
primary sensory neurons (see the General Investigations 
section). The neuropathy is usually chronic and slowly 
progressive but can also have a relapsing course. Elec-
trodiagnostic studies and nerve biopsy show both demy-
elinating and axonal features. A partial response to IVIg 
and rituximab sometimes occurs (91).
Toxic or Chemotherapy-Induced SNN
Chemotherapy-induced peripheral neurotoxicity is a 
common and potentially disabling side effect of some 
widely used anticancer agents and can be a pure sen-
sory and painful neuropathy (with thalidomide, 
cisplatin,oxaliplatin, or carboplatin) or a mixed senso-
rimotor neuropathy with or without involvement of 
the autonomic nervous system (with vincristine, pacli-
taxel, bortezomib, or suramin) (20,21,92,93). With vinca 
alkaloids and platinum analogues, a so-called coasting 
phenomenon due to a delayed release of the toxic drugs 
accumulated in tissues and is responsible for the devel-
opment or worsening of the neuropathy up to several 
weeks after treatment interruption (93). In all cases, the 
neurotoxicity significantly interferes with function and 
compromises the quality of life. In general, the periph-
eral nervous system has a great capacity for regenera-
tion in response to injury, but for regeneration to occur, 
the cell body must be spared, and this is not the case in 
SNN associated with thalidomide, cisplatin, oxaliplatin, 
or carboplatin.
Depending on the dosage and agent used, symptoms 
sometimes resolve completely, but in most instances, 
chemotherapy-induced peripheral neurotoxicity is only 
partly reversible even when the tumor has been success-
fully treated by the drugs. In individual cases, neuropa-
thy can evolve even after a single application of the drug. 
A general predisposition for developing chemotherapy-
induced neuropathy has been observed innerves previ-
ously damaged by diabetes mellitus, alcohol, or inherited 
neuropathy (94). The incidence varies depending on the 
conditions. Severe neuropathy can occur in 3% to 7% of 
patients treated with single but in up to 38% of those 
receiving polychemotherapy regimens. The neurotox-
icity of cisplatin and carboplatin is well documented. 
The first signs of the predominantly SNN appear about 
1 month after initiation of therapy. The extent of the 
neuropathy correlates with the cumulative dose of the 
platinum compound but also depends on the dose re-
ceived at each administration. Neuropathy can follow 
exposure to amounts as low as 200 mg/m2, but doses 
above 400 mg/m2 always lead to neuronal damage (21). 
The clinical picture of the neuropathy is a predomi-
nantly SNN with diminished vibration perception, 
loss of tendon reflexes, and discomforting paresthe-
sias, starting in the lower extremities. The intensity of 
paresthesias ranges from light tingling to extensive 
pain. In advanced stages, the patient is ataxic, with a 
pronounced gait disturbance due to impaired proprio-
ception; other symptoms include muscle cramps and 
lhermitte phenomenon or a similar perception con-
sisting of an electrical sensation in the shoulder girdle. 
This is due to demyelination of the dorsal roots and 
columns. Electrodiagnostic studies detect low SAP am-
plitude and secondary demyelinating neuropathy (re-
duced nerve conduction velocity) relatively late after 
the clinical manifestation of symptoms. The sural nerve 
is the most sensitive indicator for the neuropathy. Mo-
tor nerves are normally spared. oxaliplatin is a plati-
num analog similar to the approved drugs, cisplatin 
and carboplatin. The most common toxicity resulting 
from oxaliplatin therapy is neurotoxicity, with early 
neuromyotonic discharges and then cold-sensitive par-
esthesias, which are unique among the manifestations 
of platinum complexes studied to date. They occur at 
low total cumulative doses, are always reversible, and 
do not require discontinuation of therapy. However, a 
peripheral sensory neuropathy also occurs, with symp-
toms similar to those of cisplatin. The risk of develop-
ing a severe neurological disturbance is related to the 
cumulative dose, generally becoming a clinical problem 
when the cumulative dose approximates 800 mg/m2. It 
is reversible but may last for several months and may 
even require discontinuation of treatment. The mecha-
nism of neurotoxicity induced by platinum drugs may 
involve the accumulation of platinum within DRG cells. 
However, in contrast to cisplatin, oxaliplatin leads to 
retention of platinum due to slower clearance rather 
than greater accumulation.
Currently, there is no treatment that can significantly 
improve the clinical signs and symptoms of chemotherapy-
induced peripheral neurotoxicity or SNN. Symptomatic 
treatment of paresthesias and pain with ion-channel 
blockers, such as carbamazepine or gabapentin, has 
proved effective. Carbamazepine (600–1200 mg daily) 
is particularly effective in the treatment of early hyper-
pathic symptoms under oxaliplatintherapy. Tricyclic an-
tidepressants are also used as first-line therapy. Different 
strategies to prevent neuropathy have been developed 
in experimental models, and some have reached clinical 
application; these include adrenocorticotropic hormone 
analogues, amifostine (an organic thiophosphate), re-
duced glutathione, insulin-like growth factor 1, nerve 
growth factor, and neurotrophin 3. This is a heteroge-
neous group of compounds, most of which have failed 
to show any benefit in preclinical trials. Prophylactic 
measures for chemotherapy-induced neuropathies are a 
real challenge. In animal models with neuropathies in-
duced by cisplatin, vincristine, or taxol growth factors, 
neuroprotective compounds or gene therapy resulted 
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in neuroprotection (95). A recently published double-
blind vs placebo clinical trial showed that vitamin E 
(a-tocopherol 400 mg/d) may have a neuroprotective 
effect (96).
SNN and Pyridoxine Toxicity
Although pyridoxine (vitamin B6) deficiency causes 
distal, predominantly sensory neuropathy pyridoxine 
has also been identified as a neurotoxicant. During the 
1980s, the medical community was alerted to a neuro-
logical disease occurring in individuals consuming large 
quantities of vitamin B6 for prolonged periods of time 
(97,98). Since then, many more cases of pyridoxine neu-
ropathy, some patients taking as little as 200 mg/d, have 
been described (22,99). It can occur with chronic use of 
pyridoxine supplementation over several years and also 
with acute overdosage with parenteral pyridoxine (100). 
A normal adult will require 1 to 2 mg of pyridoxine 
per day. This is adequately supplied by a normal diet. 
Requirements are increased in pregnancy, in malnour-
ished patients, and in patients who are taking drugs that 
cause a depletion of pyridoxine, for example, isoniazid, 
theophyllines, and penicillamine.
Patients with pyridoxine neuropathy present a pure 
sensory neuropathy with signs of large-fiber sensory 
involvement, resulting in a pronounced sensory ataxia. 
Except for minimal weakness, there is no evidence of 
motor involvement. No sign of central nervous system 
dysfunction, except a transient lhermitte phenomenon, 
has been described. Neurological disability gradually 
improves with discontinuation of pyridoxine. Although 
there are no recent data on the prevalence of pyridoxine-
induced SNN, this condition should be considered in a 
patient presenting with a sensory neuropathy. In animal 
models, pyridoxine intoxication causes a predominant, 
but not exclusive, degeneration of large-diameter neu-
rons in the DRG and the large sensory fibers derived 
from those neurons (99,101). This pattern is supported 
by electrodiagnostic data showing a decrement in the 
H-wave amplitude but no change in the direct motor 
response.
Non–Length-Dependent Small-Fiber  
Ganglionopathy
The syndrome of small-fiber ganglionopathy with early 
involvement of the face, trunk, or proximal limbs is not 
well recognized and contrasts with the burning feet 
syndrome of small-fiber neuropathy and classical large 
fiber features of sensory ganglionopathy. Twelve men 
and 11 women, with an average age of 50 years, were re-
ported from 4 centers (27). Neuropathic pain developed 
over days or over months. The pain was characterized 
as burning, prickling, shooting, or allodynic. There was 
loss of pinprick sensation in affected regions in 19, with 
minimal or no loss of large fiber sensibility. labora-
tory findings included abnormal glucose metabolism in 
6 patients, Sjögren syndrome in 3, and monoclonal gam-
mopathy, sprue, and hepatitis C infection in 1 each, with 
the remainder idiopathic. SAPs were normal in 12 and 
were reduced in the hands but normal in the legs in 6. 
Skin biopsy in 14 of 17 showed reduced nerve fiber den-
sity in the thigh equal to or more prominent than in the 
calf. Two of 7 patients improved with immune thera-
pies, 13 symptomatically with analgesic medications. 
Ten considered the pain disabling at the last follow-up.
Inherited Disorders With  
Degeneration of DRG Cells
Friedreich Ataxia
friedreich ataxia, an autosomal recessive neurodegener-
ative disease, is the most common of the inherited atax-
ias (102) and the most frequently encountered inherited 
ataxia with electrodiagnostic features of SNN (103). The 
cardinal clinical features are progressive gait and limb 
ataxia, absent lower limb reflexes, extensor plantar re-
sponses, dysarthria, and reduction in or loss of vibration 
sense and proprioception. Cardiomyopathy, scoliosis, 
and foot deformity are common but nonessential fea-
tures. The phenotype spectrum is broader than previ-
ously considered, suggesting the usefulness of genetic 
testing of the FRDA gene in all patients with idiopathic 
ataxia (104).
Ataxia With Vitamin E Deficiency
Ataxia with vitamin E deficiency is a rare autosomal re-
cessive neurodegenerative disease, due to mutations in 
TTPA gene (105), which encodes for a-TTP, a cytosolic 
liver protein that is presumed to function in the intra-
cellular transport of a-tocopherol. This disease is char-
acterized clinically by symptoms with often striking 
resemblance to those of friedreich ataxia. The neurolog-
ical symptoms include ataxia, dysarthria, hyporeflexia, 
and decreased vibration sense, sometimes associated 
with cardiomyopathy and retinitis pigmentosa (106). 
Vitamin E supplementation improves symptoms and 
prevents disease progress (107).
Abetalipoproteinemia
A SNN can be observed in familial hypocholester-
olemia, namely abetalipoproteinemia, hypobetalipo-
proteinemia, and chylomicron retention disease, a rare 
genetic disease that causes malnutrition and growth 
failure. The diagnosis is based on a history of chronic 
diarrhea with fat malabsorption and abnormal lipid 
profile. upper endoscopy and histology reveal fat-laden 
enterocytes, whereas vitamin E deficiency is invariably 
present. Creatine kinase (Ck) is usually elevated and 
hepatic steatosis is common. Genotyping identifies the 
Sar1b gene mutation. Treatment and follow-up remain 
poorly defined (108).
Mitochondrial Disorders
Several phenotypes previously referred to as mitochon-
drial recessive ataxia syndrome (MIRAS) and sensory 
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ataxia neuropathy dysarthria and ophthalmoplegia 
(SANDo) harbor proprioceptive ataxia, with oph-
thalmoplegia, and have been reported in relation with 
nuclear mutation of the mitochondrial DNA with muta-
tion of the polymerase g (POLG) gene (109). The enlarg-
ing spectrum of sensory ataxic neuropathies associated 
with mitochondrial DNA (mtDNA) instability and 
POLG mutations should be recognized and considered 
in the differential diagnosis of this unusual presenta-
tion. Despite a growing appreciation of mitochondrial 
SNN phenotypes, there are a number of potential pitfalls 
in relation to confirming a diagnosis. first, the POLG- 
associated diseases are widely heterogeneous, and 
within the sensory ataxic phenotypes, there may be 
much overlap between syndromes as well as absence or 
delayed emergence of certain features such as ophthal-
moparesis (108). Second, muscle biopsy may be normal, 
and multiple mtDNA deletions may be difficult to dem-
onstrate (110).
Combined SNN and Motor Neuron Disorders
The combination of severe sensory and motor neu-
ronopathy is rarely encountered in clinical practice. It 
has been reported in patients with paraneoplastic Hu 
antibodies (see above), in facial onset sensory and motor 
neuronopathy (111), and in rare genetic diseases such as 
Tangier disease and the A382P TDP-43 mutation in the 
TARDBP gene (112).
DIFFERENTIAL DIAGNOSIS
The differential diagnosis involves distinguishing SNN 
from other sensory polyneuropathies, diseases primar-
ily affecting posterior column fibers being beyond the 
scope of this discussion (Table 20.2).
Infectious Ataxic Neuropathies
In the preantibiotic era, syphilis was the most frequent 
cause of myelopathy (113). Patients presented with sen-
sory levels, lower extremity weakness, pyramidal signs, 
and variable degrees of bladder and bowel dysfunc-
tion but also with polyradiculopathy. Pathologies have 
been related to meningomyelitis, meningovascular dis-
ease, and cord atrophy (tabes dorsalis) and also to cord 
compression from gummae or syphilitic osteitis. Tabes 
dorsalis is caused by the degeneration of the postgan-
glionic sensory nerve roots and dorsal columns of the 
spinal cord due to syphilitic pachymeningitis, especially 
at the lower thoracic and lumbar levels. This results in 
abolished or reduced tendon reflexes, ataxia, loss of pain 
sensation, foot ulcers, arthropathy, and lancinating pain. 
In contrast to peripheral neuropathy or ganglionopathy, 
SAPs are normal. Guidelines recommend treatment of 
neurosyphilis with 18 to 24 million units of intravenous 
aqueous penicillin per day for 10 to 14 days.
Diphtheric Polyneuropathy
Diphtheric polyneuropathy occurs in 15% of patients 
after severe pharyngeal infection. The most frequent 
manifestations include bulbar paralysis or a demyeli-
nating disorder resembling GBS (114). Impairment of 
deep sensation is frequent and, in some cases, can result 
in an ataxic pseudotabetic neuropathy.
Human T-Cell Lymphotropic Virus
Human T-cell lymphotropic virus I or II has been associ-
ated with some cases of tropical ataxic neuropathy (see 
below) (115,116).
HIV
Peripheral neuropathy is a common complication of 
HIV infection and has a broad spectrum of manifesta-
tions. The most frequent is a predominantly sensory and 
painful distal neuropathy, which is almost universal in 
the late stages of HIV infection. However, a few pa-
tients have been reported with a subacute ataxic sensory 
ganglionopathy (11,12).
Tropical Ataxic Neuropathies
Tropical ataxic neuropathies encompass a heteroge-
neous group of disorders characterized by an ataxic 
syndrome associated with other manifestations, includ-
ing paraparesis, optic nerve involvement, and mental 
disorders (117). Most of these are caused by nutritional 
factors and attributed to toxiconutritional causes. The 
disorder has been reported in prisoners of war (Stra-
chan syndrome) and as epidemic neuropathy in Cuba, 
epidemic paralytic disease (konzo) in Congo, and in 
Nigeria.
Demyelinating Neuropathies
The EfNS/PNS guidelines on the definition, investi-
gation, and treatment of chronic inflammatory demy-
elinating polyradiculoneuropathy and of patients with 
paraproteinemic demyelinating neuropathy have been 
recently revised (118,119). These 2 neuropathies are the 
most common differential diagnosis of SNN.
CONCLUSIONS
SNN is a clinically, histologically, and pathogeneti-
cally distinct category of sensory neuropathy. Although 
it may not be easy to separate ganglionopathies from 
other sensory ataxic neuropathies, electrodiagnostic 
studies are useful in demonstrating an asymmetrical or 
multifocal reduction in amplitude of the proximal and 
distal SAPs. one important factor in the pathogenesis 
is the access of the autoantibodies to the target antigen 
in the central and peripheral nervous system in dysim-
mune and paraneoplastic neuronopathies. Dysimmune 
sensory ganglionitis may be responsive to immunosup-
pressive therapy, whereas the paraneoplastic, toxic neu-
ronopathies, and associated SNN with genetic diseases 
are generally refractory. There is a great need to expand 
the number of confirmed therapies and explore treat-
ments that could potentially stop or reverse damage to 
the DRG.
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Those disorders are characterized by primary •	
degeneration of sensory neurons in DRG. They 
encompass neoplastic or dysimmune causes 
and toxic agents and are more rarely encoun-
tered with genetic disorders.
Non-length–dependent distribution of sensory •	
loss and almost pure EDX sensory involvement 
are the distinctive signs, but in neoplastic SNN, 
combined neurological manifestations, such as 
autonomic neuropathy, motor neuron disorder, 
limbic dysfunction, or cerebellar signs usually 
occur.
Investigations include EDX studies (all cases), •	
imaging techniques (neoplastic cases), blood 
and biological parameters, CSf examination 
(all cases except toxic), sural nerve biopsy (dys-
immune cases), as well as genetic testing (selec-
tive cases).
Diagnosis of SNN is possible based on exami-•	
nation and on results of the EDX studies, prob-
able as related to the biological workup and 
imaging data, and definite if DRG degenera-
tion is pathologically proven (DRG biopsy not 
recommended). A validated score to recognize 
SNN independently of the underlying cause is 
available.
Treatments are tailored to the underlying cause.•	
Graus f, Campo E, Cruz-Sanchez f, Ribalta T, Palacin A. 9. 
Expression of lymphocyte, macrophage and class I and II 
major histocompatibility complex antigens in normal hu-
man dorsal root ganglia. J Neurol Sci. 1990;98:203–211.
Wanschitz J, Hainfellner JA, kristoferitsch W, Drlicek 10. 
M, Budka H. Ganglionitis in paraneoplastic subacute 
sensory neuronopathy: a morphologic study. Neurology. 
1997;49:1156–1159.
Esiri MM, Morris CS, Millard PR. Sensory and sympa-11. 
thetic ganglia in HIV-1 infection: immunocytochemical 
demonstration of HIV-1 viral antigens, increased MHC 
class II antigen expression and mild reactive inflamma-
tion. J Neurol Sci. 1993;114:178–187.
Scaravilli f, Sinclair E, Arango JC, Manji H, lucas S, Har-12. 
rison MJ. The pathology of the posterior root ganglia in 
AIDS and its relationship to the pallor of the gracile tract. 
Acta Neuropathol. 1992;84:163–170.
Colli Bo, Carlotti CG Jr, Assirati JA Jr, lopes lS, 13. 
Marques W, Jr, Chimelli l, Neder l, Barreira AA. Dorsal 
root ganglionectomy for the diagnosis of sensory neuropa-
thies. Surgical technique and results. Surg Neurol. 2008;69: 
266–273.
Griffin JW, Cornblath DR, Alexander E, Campbell J, low 14. 
PA, Bird S, feldman El. Ataxic sensory neuropathy and 
dorsal root ganglionitis associated with Sjögren’s syn-
drome. Ann Neurol. 1990;27:304–315.
Hainfellner JA, kristoferitsch W, lassmann H, Bernheimer 15. 
H, Neisser A, Drlicek M, Beer f, Budka H. T-cell–mediated 
ganglionitis associated with acute sensory neuronopathy. 
Ann Neurol. 1996;39:543–547.
kurokawa k, Noda k, Mimori y, Watanabe C, katayama 16. 
S, Nakamura S, Sannomiya k, yamamoto S, Tahara E. A 
case of pandysautonomia with associated sensory gangli-
onopathy. J Neurol Neurosurg Psychiatry. 1998;65:278–279.
okajima T, yamamura S, Hamada k, kawasaki S, Ideta 17. 
T, ueno H, Tokuomi H. Chronic sensory and autonomic 
neuropathy. Neurology. 1983;33:1061–1064.
Sobue G, yanagi T, Hashizume y. Chronic progressive 18. 
sensory ataxic neuropathy with polyclonal gammopathy 
and disseminated focal perivascular cellular infiltrations. 
Neurology. 1988;38:463–467.
Mori k, Iijima M, koike H, Hattori N, Tanaka f, Watanabe 19. 
H, katsuno M, fujita A, Aiba I, ogata A, Saito T, Asakura k, 
yoshida M, Hirayama M, Sobue G. The wide spectrum of 
clinical manifestations in Sjögren’s syndrome–associated 
neuropathy. Brain. 2005;128:11–34.
Gill JS, Windebank AJ. Cisplatin-induced apoptosis in 20. 
rat dorsal root ganglion neurons is associated with at-
tempted entry into the cell cycle. J Clin Invest. 1998;101: 
2842–2850.
krarup-Hansen A, Helweg-larsen S, Schmalbruch H, 21. 
Rorth M, krarup C. Neuronal involvement in cisplatin 
neuropathy: prospective clinical and neurophysiological 
studies. Brain. 2007;130:4–88.
Windebank AJ, low PA, Blexrud MD, Schmelzer JD, 22. 
Schaumburg HH. Pyridoxine neuropathy in rats: specific 
degeneration of sensory axons. Neurology. 1985;35:1617–
1622.
Xu y, Sladky JT, Brown MJ. Dose-dependent expression of 23. 
neuronopathy after experimental pyridoxine intoxication. 
Neurology. 1989;39:1077–1083.
kusunoki S, Shimizu J, Chiba A, ugawa y, Hitoshi S, 24. 
k anazawa I. Experimental sensory neuropathy induced 
REFERENCES
kuntzer T, Antoine JC, Steck AJ. Clinical features and 1. 
pathophysiological basis of sensory neuronopathies (gan-
glionopathies). Muscle Nerve. 2004;30:255–268.
Sghirlanzoni A, Pareyson D, lauria G. Sensory neuron 2. 
diseases. Lancet Neurol. 2005;4:349–361.
Smith BE, Windebank AJ, Dyck PJ. Nonmalignant inflam-3. 
matory sensory polyganglionopathy. In: Dyck PJ, Thomas 
Pk, eds. Peripheral Neuropathy. 4th ed. Philadelphia: El-
sevier Saunders; 2005:2309–2320.
kuntzer T. [Ganglionopathies: evolving concept and ideas 4. 
on management]. Rev Neurol (Paris). 2006;162:1268–1272.
Denny-Brown D. Primary sensory neuropathy with mus-5. 
cular changes associated with carcinoma. J Neurol Neuro-
surg Psychiatry. 1948,73–87.
Denny-Brown D. Hereditary sensory radicular neuropa-6. 
thy. J Neurol Neurosurg Psychiatry. 1951;14:237–252.
Spies JM, Mcleod JG. Paraneoplastic neuropathy. In: Dyck 7. 
PJ, Thomas Pk, eds. Peripheral Neuropathy. 4th ed. Phila-
delphia: Elsevier Saunders; 2005:2471–2487.
Dalmau J, furneaux HM, Rosenblum Mk, Graus f, Pos-8. 
ner JB. Detection of the anti-Hu antibody in specific re-
gions of the nervous system and tumor from patients with 
paraneoplastic encephalomyelitis/sensory neuronopathy. 
Neurology. 1991;41:1757–1764.
CLINICAL PEARLS AND KEY POINTS IN  
SENSORY NEURONOPATHIES (SNN)
Donofrio_R1_CH20_02-17-2012_273-288.indd           284                            Manila Typesetting Company                         02/17/2012  05:47PM Donofrio_R1_CH20_02-17-2012_273-288.indd           285                            Manila Typesetting Company                         02/17/2012  05:47PM
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
286 TEXTBook of PERIPHERAl NEuRoPATHy
by sensitization with ganglioside GD1b. Ann Neurol. 1996; 
39:424–431.
Asbury Ak. Sensory neuronopathy. 25. Semin Neurol. 
1987;7:58–66.
Camdessanche JP, Jousserand G, ferraud k, Vial C, Petiot 26. 
P, Honnorat J, Antoine JC. The pattern and diagnostic cri-
teria of sensory neuronopathy: a case-control study. Brain. 
2009;132:7–33.
Gorson kC, Herrmann DN, Thiagarajan R, Brannagan TH, 27. 
Chin Rl, kinsella lJ, Ropper AH. Non-length dependent 
small fibre neuropathy/ganglionopathy. J Neurol Neuro-
surg Psychiatry. 2008;79:163–169.
lauria G, Pareyson D, Sghirlanzoni A. Neurophysiologi-28. 
cal diagnosis of acquired sensory ganglionopathies. Eur 
Neurol. 2003;50:146–152.
Windebank AJ, Blexrud MD, Dyck PJ, Daube JR, karnes 29. 
Jl. The syndrome of acute sensory neuropathy: clinical 
features and electrophysiologic and pathologic changes. 
Neurology. 1990;40:584–591.
Griffin JW, Cornblath DR, Alexander E, Campbell J, low 30. 
PA, Bird S, feldman El. Ataxic sensory neuropathy and 
dorsal root ganglionitis associated with Sjögren’s syn-
drome. Ann Neurol. 1990;27:304–315.
Auger RG, Windebank AJ, lucchinetti Cf, Chalk CH. Role 31. 
of the blink reflex in the evaluation of sensory neuronopa-
thy. Neurology. 1999;53:407.
Mori k, koike H, Misu k, Hattori N, Ichimura M, Sobue 32. 
G. Spinal cord magnetic resonance imaging demonstrates 
sensory neuronal involvement and clinical severity in 
neuronopathy associated with Sjögren’s syndrome. J Neu-
rol Neurosurg Psychiatry. 2001;71:488–492.
Dalakas MC. Chronic idiopathic ataxic neuropathy. 33. Ann 
Neurol. 1986;19:545–554.
Graus f, Delattre Jy, Antoine JC, Dalmau J, Giometto B, 34. 
Grisold W, Honnorat J, Smitt PS, Vedeler C, Verschuuren 
JJ, Vincent A, Voltz R. Recommended diagnostic criteria 
for paraneoplastic neurological syndromes. J Neurol Neu-
rosurg Psychiatry. 2004;75:1135–1140.
Graus f, Cordon-Cardo C, Posner JB. Neuronal antinu-35. 
clear antibody in sensory neuronopathy from lung cancer. 
Neurology. 1985;35:538–543.
Giometto B, Grisold W, Vitaliani R, Graus f, Honnorat J, 36. 
Bertolini G. Paraneoplastic neurologic syndrome in the 
PNS Euronetwork database: a European study from 20 
centers. Arch Neurol. 2010;67:330–335.
Ilyas AA, Quarles RH, Dalakas MC, fishman PH, Brady 37. 
Ro. Monoclonal IgM in a patient with paraproteinemic 
polyneuropathy binds to gangliosides containing disialo-
syl groups. Ann Neurol. 1985;18:655–659.
Susuki k, yuki N, Hirata k. features of sensory ataxic 38. 
neuropathy associated with anti-GD1b IgM antibody. 
J Neuroimmunol. 2001;112:181–187.
Willison HJ, o’leary CP, Veitch J, Blumhardt lD, Busby 39. 
M, Donaghy M, fuhr P, ford H, Hahn A, Renaud S, kat-
ifi HA, Ponsford S, Reuber M, Steck A, Sutton I, Schady 
W, Thomas Pk, Thompson AJ, Vallat JM, Winer J. The 
clinical and laboratory features of chronic sensory ataxic 
neuropathy with anti-disialosyl IgM antibodies. Brain. 
2001;124:1968–1977.
kusunoki S, Mashiko H, Mochizuki N, Chiba A, Arita 40. 
M, Hitoshi S, kanazawa I. Binding of antibodies against 
GM1 and GD1b in human peripheral nerve. Muscle Nerve. 
1997;20:840–845.
kusunoki S, Hitoshi S, kaida k, Arita M, kanazawa I. 41. 
Monospecific anti-GD1b IgG is required to induce rabbit 
ataxic neuropathy. Ann Neurol. 1999;45:400–403.
Henson RA, urich H. Encephalomyelitis with carcinoma. 42. 
In: Henson RA, urich H, eds. Cancer and the Nervous Sys-
tem. oxford: Blackwell Scientific; 1982:314–345.
Smeenk RJ. Antinuclear antibodies: cause of disease or 43. 
caused by disease? Rheumatology (Oxf). 2000;39:581–584.
Tanaka k, Tanaka M, Inuzuka T, Nakano R, Tsuji S. Cyto-44. 
toxic T lymphocyte–mediated cell death in paraneoplastic 
sensory neuronopathy with anti-Hu antibody. J Neurol Sci. 
1999;163:159–162.
Benyahia B, liblau R, Merle-Beral H, Tourani JM, Dalmau 45. 
J, Delattre Jy. Cell-mediated autoimmunity in paraneo-
plastic neurological syndromes with anti-Hu antibodies. 
Ann Neurol. 1999;45:162–167.
Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. 46. 
Neurological paraneoplastic syndromes in patients with 
small cell lung cancer. A prospective survey of 150 pa-
tients. J Neurol Neurosurg Psychiatry. 1991;54:764–767.
van oosterhout AG, van de Pol M, ten Velde GP, Twijnstra 47. 
A. Neurologic disorders in 203 consecutive patients with 
small cell lung cancer. Results of a longitudinal study. 
Cancer. 1996;77:1434–1441.
Croft P, Wilkinson M. Carcinomatous neuromyopathy. Its 48. 
incidence in patients with carcinoma of the lung and car-
cinoma of the breast. Lancet. 1963;1:184–188.
Antoine JC, Mosnier Jf, Absi l, Convers P, Honnorat J, 49. 
Michel D. Carcinoma associated paraneoplastic periph-
eral neuropathies in patients with and without anti-
onconeural antibodies. J Neurol Neurosurg Psychiatry. 
1999;67:7–14.
Camdessanche JP, Antoine JC, Honnorat J, Vial C, Pe-50. 
tiot P, Convers P, Michel D. Paraneoplastic peripheral 
neuropathy associated with anti-Hu antibodies. A clini-
cal and electrophysiological study of 20 patients. Brain. 
2002;125:166–175.
Chalk CH, Windebank AJ, kimmel DW, McManis PG. 51. 
The distinctive clinical features of paraneoplastic sensory 
neuronopathy. Can J Neurol Sci. 1992;19:346–351.
Horwich MS, Cho l, Porro RS, Posner JB. Subacute sen-52. 
sory neuropathy: a remote effect of carcinoma. Ann Neu-
rol. 1977;2:7–19.
Graus f, Rene R. Paraneoplastic neuropathies. 53. Eur 
Neurol.1993;33:279–286.
Graus f, keime-Guibert f, Rene R, Benyahia B, Ribalta T, 54. 
Ascaso C, Escaramis G, Delattre Jy. Anti-Hu–associated 
paraneoplastic encephalomyelitis: analysis of 200 patients. 
Brain. 2001;124:1138–1148.
Dalmau J, Graus f, Rosenblum Mk, Posner JB. Anti-Hu–55. 
associated paraneoplastic encephalomyelitis/sensory 
neuronopathy. A clinical study of 71 patients. Medicine 
(Baltimore) 1992;71:59–72.
Saiz A, Bruna J, Stourac P, Vigliani MC, Giometto B, Gri-56. 
sold W, Honnorat J, Psimaras D, Voltz R, Graus f. Anti-
Hu–associated brainstem encephalitis. J Neurol Neurosurg 
Psychiatry. 2009;80:404–407.
Sillevis SP, Grefkens J, de lB, van den Bent M, van PW, 57. 
Hooijkaas H, Vecht C. Survival and outcome in 73 anti-Hu 
positive patients with paraneoplastic encephalomyelitis/
sensory neuronopathy. J Neurol. 2002;249:745–753.
lucchinetti Cf, kimmel DW, lennon VA. Paraneoplas-58. 
tic and oncologic profiles of patients seropositive for 
Donofrio_R1_CH20_02-17-2012_273-288.indd           286                            Manila Typesetting Company                         02/17/2012  05:47PM
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
Donofrio_R1_CH20_02-17-2012_273-288.indd           287                            Manila Typesetting Company                         02/17/2012  05:47PM
CHAPTER 20: SENSoRy NEuRoNoPATHIES oR GANGlIoNoPATHIES 287
type 1 antineuronal nuclear autoantibodies. Neurology. 
1998;50:652–657.
Antoine JC, Cinotti l, Tilikete C, Bouhour f, Camdes-59. 
sanche JP, Confavreux C, Vighetto A, Renault-Mannel 
V, Michel D, Honnorat J. [18f]fluorodeoxyglucose posi-
tron emission tomography in the diagnosis of cancer in 
patients with paraneoplastic neurological syndrome and 
anti-Hu antibodies. Ann Neurol. 2000;48:105–108.
Rees JH, Hain Sf, Johnson MR, Hughes RA, Costa DC, Ell PJ, 60. 
keir G, Rudge P. The role of [18f]fluoro-2-deoxyglucose- 
PET scanning in the diagnosis of paraneoplastic neuro-
logical disorders. Brain. 2001;124:2223–2231.
Molinuevo Jl, Graus f, Serrano C, Rene R, Guerrero A, Illa 61. 
I. utility of anti-Hu antibodies in the diagnosis of paraneo-
plastic sensory neuropathy. Ann Neurol. 1998;44:976–980.
llado A, Mannucci P, Carpentier Af, Paris S, Blanco y, 62. 
Saiz A, Delattre Jy, Graus f. Value of Hu antibody deter-
minations in the follow-up of paraneoplastic neurologic 
syndromes. Neurology. 2004;63:1947–1949.
keime-Guibert f, Graus f, fleury A, Rene R, Honnorat J, 63. 
Broet P, Delattre Jy. Treatment of paraneoplastic neuro-
logical syndromes with antineuronal antibodies (anti-Hu, 
anti-yo) with a combination of immunoglobulins, cyclo-
phosphamide, and methylprednisolone. J Neurol Neuro-
surg Psychiatry. 2000;68:479–482.
Blaes f, Strittmatter M, Merkelbach S, Jost V, klotz M, 64. 
Schimrigk k, Hamann Gf. Intravenous immunoglobulins 
in the therapy of paraneoplastic neurological disorders. 
J Neurol. 1999;246:299–303.
uchuya M, Graus f, Vega f, Rene R, Delattre Jy. Intra-65. 
venous immunoglobulin treatment in paraneoplastic neu-
rological syndromes with antineuronal autoantibodies. 
J Neurol Neurosurg Psychiatry. 1996;60:388–392.
Mowzoon N, Bradley WG. Successful immunosuppres-66. 
sant therapy of severe progressive cerebellar degenera-
tion and sensory neuropathy: a case report. J Neurol Sci. 
2000;178:63–65.
oh SJ, Dropcho EJ, Claussen GC. Anti-Hu–associated 67. 
paraneoplastic sensory neuropathy responding to early 
aggressive immunotherapy: report of two cases and re-
view of literature. Muscle Nerve. 1997;20:1576–1582.
Coret f, Bosca I, fratalia l, Perez-Griera J, Pascual A, Casa-68. 
nova B. long-lasting remission after rituximab treatment 
in a case of anti-Hu–associated sensory neuronopathy and 
gastric pseudoobstruction. J Neurooncol. 2009;93:421–423.
van Bf, de Graaf MT, Bromberg JE, Hooijkaas H, van den 69. 
Bent MJ, de Beukelaar JW, khan NA, Gratama JW, van der 
Geest JN, frens M, Benner R, Sillevis Smitt PA. Human 
chorionic gonadotropin treatment of anti-Hu–associated 
paraneoplastic neurological syndromes. J Neurol Neurosurg 
Psychiatry. 2010;81:1341–1344.
Dyck PJ, Gutrecht JA, Bastron JA, karnes WE, Dale AJ. 70. 
Histologic and teased-fiber measurements of sural nerve 
in disorders of lower motor and primary sensory neurons. 
Mayo Clin Proc. 1968;43:81–123.
Sterman AB, Schaumburg HH, Asbury Ak. The acute sen-71. 
sory neuronopathy syndrome: a distinct clinical entity. 
Ann Neurol. 1980;7:354–358.
Malinow k, yannakakis GD, Glusman SM, Edlow DW, 72. 
Griffin J, Pestronk A, Powell Dl, Ramsey-Goldman R, 
Eidelman BH, Medsger TA Jr. Subacute sensory neuro-
nopathy secondary to dorsal root ganglionitis in primary 
Sjögren’s syndrome. Ann Neurol. 1986;20:535–537.
Grant IA, Hunder GG, Homburger HA, Dyck PJ. Periph-73. 
eral neuropathy associated with sicca complex. Neurology. 
1997;48:855–862.
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, 74. 
 Alexander El, Carsons SE, Daniels TE, fox PC, fox RI, 
kassan SS, Pillemer SR, Talal N, Weisman MH. Classifica-
tion criteria for Sjögren’s syndrome: a revised version of 
the European criteria proposed by the American-European 
Consensus Group. Ann Rheum Dis. 2002;61:554–558.
Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del 75. 
Pino-Montes J, Calvo-Alen J, Jimenez-Alonso J, Mico Ml, 
Beltran J, Belenguer R, Pallares l. Primary Sjögren syn-
drome in Spain: clinical and immunologic expression in 
1010 patients. Medicine (Baltimore). 2008;87:210–219.
Hansen A, lipsky PE, Dorner T. Immunopathogenesis 76. 
of primary Sjögren’s syndrome: implications for dis-
ease management and therapy. Curr Opin Rheumatol. 
2005;17:558–565.
Thanou-Stavraki A, James JA. Primary Sjögren’s syn-77. 
drome: current and prospective therapies. Semin Arthritis 
Rheum. 2008;37:273–292.
Chen WH, yeh JH, Chiu HC. Plasmapheresis in the 78. 
treatment of ataxic sensory neuropathy associated with 
Sjögren’s syndrome. Eur Neurol. 2001;45:270–274.
Takahashi y, Takata T, Hoshino M, Sakurai M, ka-79. 
nazawa I. Benefit of IVIG for long-standing ataxic sen-
sory neuronopathy with Sjögren’s syndrome. Neurology. 
2003;60:503–505.
Molina JA, Benito-leon J, Bermejo f, Jimenez-Jimenez fJ, 80. 
olivan J. Intravenous immunoglobulin therapy in sensory 
neuropathy associated with Sjögren’s syndrome. J Neurol 
Neurosurg Psychiatry. 1996;60:699.
Pascual J, Cid C, Berciano J. High-dose i.v. immunoglobu-81. 
lin for peripheral neuropathy associated with Sjögren’s 
syndrome. Neurology. 1998;51:650b–6651.
yamada S, Mori k, Matsuo k, Inukai A, kawagashira y, 82. 
Sobue G. Interferon alfa treatment for Sjögren’s syndrome 
associated neuropathy. J Neurol Neurosurg Psychiatry. 
2005;76:576–578.
Caroyer JM, Manto Mu, Steinfeld SD. Severe sensory neu-83. 
ronopathy responsive to infliximab in primary Sjögren’s 
syndrome. Neurology. 2002;59:1113–1114.
Gorson kC, Natarajan N, Ropper AH, Weinstein R. Ritux-84. 
imab treatment in patients with IVIg-dependent immune 
polyneuropathy: a prospective pilot trial. Muscle Nerve. 
2007;35:66–69.
yuki N. fisher syndrome and Bickerstaff brainstem en-85. 
cephalitis (fisher-Bickerstaff syndrome). J Neuroimmunol. 
2009;215:1–9.
Ito M, kuwabara S, odaka M, Misawa S, koga M, Hirata 86. 
k, yuki N. Bickerstaff’s brainstem encephalitis and fisher 
syndrome form a continuous spectrum: clinical analysis of 
581 cases. J Neurol. 2008;255:674–682.
Willison HJ, o’Hanlon GM, Paterson G, Veitch J, Wilson 87. 
G, Roberts M, Tang T, Vincent A. A somatically mutated 
human antiganglioside IgM antibody that induces ex-
perimental neuropathy in mice is encoded by the variable 
region heavy chain gene, V1-J Clin Invest. 1996;97:1155–
1164.
liu JX, Willison HJ, Pedrosa-Domellof f. Immunolocaliza-88. 
tion of GQ1b and related gangliosides in human extraocu-
lar neuromuscular junctions and muscle spindles. Invest 
Ophthalmol Vis Sci. 2009;50:3226–3232.
Donofrio_R1_CH20_02-17-2012_273-288.indd           286                            Manila Typesetting Company                         02/17/2012  05:47PM Donofrio_R1_CH20_02-17-2012_273-288.indd           287                            Manila Typesetting Company                         02/17/2012  05:47PM
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
288 TEXTBook of PERIPHERAl NEuRoPATHy
kusunoki S, Chiba A, kanazawa I. Anti-GQ1b IgG anti-89. 
body is associated with ataxia as well as ophthalmoplegia. 
Muscle Nerve. 1999;22:1071–1074.
overell JR, Hsieh ST, odaka M, yuki N, Willison HJ. 90. 
Treatment for fisher syndrome, Bickerstaff’s brainstem 
encephalitis and related disorders. Cochrane Database Syst 
Rev. 2007,CD004761.
Delmont E, Jeandel Py, Hubert AM, Marcq l, Boucraut 91. 
J, Desnuelle C. Successful treatment with rituximab 
of one patient with CANoMAD neuropathy. J Neurol. 
2010;257:655–657.
Antoine JC, Camdessanche JP. Peripheral nervous sys-92. 
tem involvement in patients with cancer. Lancet Neurol. 
2007;6:75–86.
Quasthoff S, Hartung HP. Chemotherapy-induced pe-93. 
ripheral neuropathy. J Neurol. 2002;249:9–17.
Hildebrandt G, Holler E, Woenkhaus M, Quarch G, Re-94. 
ichle A, Schalke B, Andreesen R. Acute deterioration of 
Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg 
of vincristine chemotherapy. Ann Oncol. 2000;11:743–747.
umapathi T, Chaudhry V. Toxic neuropathy. 95. Curr Opin 
Neurol. 2005;18:574–580.
Pace A, Giannarelli D, Galie E, Savarese A, Carpano S, 96. 
Della GM, Pozzi A, Silvani A, Gaviani P, Scaioli V, Jandolo 
B, Bove l, Cognetti f. Vitamin E neuroprotection for cis-
platin neuropathy: a randomized, placebo-controlled trial. 
Neurology. 2010;74:762–766.
Dalton k, Dalton MJ. Characteristics of pyridoxine 97. 
overdose neuropathy syndrome. Acta Neurol Scand. 
1987;76:8–11.
Schaumburg H, kaplan J, Windebank A, Vick N, Rasmus 98. 
S, Pleasure D, Brown MJ. Sensory neuropathy from pyri-
doxine abuse. A new megavitamin syndrome. N Engl J 
Med. 1983;309:445–448.
Xu y, Sladky JT, Brown MJ. Dose-dependent expression of 99. 
neuronopathy after experimental pyridoxine intoxication. 
Neurology. 1989;39:1077–1083.
Albin Rl, Albers JW, Greenberg HS, Townsend JB, lynn 100. 
RB, Burke JM Jr, Alessi AG. Acute sensory neuropathy-
neuronopathy from pyridoxine overdose. Neurology. 
1987;37:1729–1732.
Chung Jy, Choi JH, Hwang Cy, youn Hy. Pyridoxine 101. 
induced neuropathy by subcutaneous administration in 
dogs. J Vet Sci. 2008;9:127–131.
Delatycki MB, Williamson R, forrest SM. friedreich ataxia: 102. 
an overview. J Med Genet. 2000;37:1–8.
Arnold P, Boulat o, Maire R, kuntzer T. Expanding view 103. 
of phenotype and oxidative stress in friedreich’s ataxia 
patients with and without idebenone. Swiss Arch Neurol 
Neurosurg Psychiatry. 2006;157:169–176.
Schols l, Amoiridis G, Przuntek H, frank G, Epplen JT, 104. 
Epplen C. friedreich’s ataxia. Revision of the phenotype 
according to molecular genetics. Brain. 1997;120:2131–
2140.
Hentati A, Deng HX, Hung Wy, Nayer M, Ahmed MS, He 105. 
X, Tim R, Stumpf DA, Siddique T, Ahmed. Human alpha-
tocopherol transfer protein: gene structure and mutations 
in familial vitamin E deficiency. Ann Neurol. 1996;39:295–
300.
Mariotti C, Gellera C, Rimoldi M, Mineri R, uziel G, Zorzi 106. 
G, Pareyson D, Piccolo G, Gambi D, Piacentini S, Squit-
ieri f, Capra R, Castellotti B, Di DS. Ataxia with isolated 
vitamin E deficiency: neurological phenotype, clinical 
follow-up and novel mutations in TTPA gene in Italian 
families. Neurol Sci. 2004;25:130–137.
Doria-lamba l, De GE, Cristiani E, fiocchi I, Montaldi l, 107. 
Grosso P, Gellera C. Efficacious vitamin E treatment in a 
child with ataxia with isolated vitamin E deficiency. Eur J 
Pediatr. 2006;165:494–495.
Peretti N, Sassolas A, Roy CC, Deslandres C, Charcosset 108. 
M, Castagnetti J, Pugnet-Chardon l, Moulin P, labarge S, 
Bouthillier l, lachaux A, levy E. Guidelines for the diag-
nosis and management of chylomicron retention disease 
based on a review of the literature and the experience of 
two centers. Orphanet J Rare Dis. 2010;5:24.
McHugh JC, lonergan R, Howley R, o’Rourke k, Taylor 109. 
RW, farrell M, Hutchinson M, Connolly S. Sensory ataxic 
neuropathy dysarthria and ophthalmoparesis (SANDo) 
in a sibling pair with a homozygous p.A467T PolG muta-
tion. Muscle Nerve. 2010;41:265–269.
Van GG, luoma P, Rantamaki M, Al MA, kaakkola S, Hack-110. 
man P, krahe R, lofgren A, Martin JJ, De JP, Suomalainen 
A, udd B, Van BC. PolG mutations in neurodegenerative 
disorders with ataxia but no muscle involvement. Neurol-
ogy. 2004;63:1251–1257.
Vucic S, Tian D, Chong PS, Cudkowicz ME, Hedley-Whyte 111. 
ET, Cros D. facial onset sensory and motor neuronopa-
thy (foSMN syndrome): a novel syndrome in neurology. 
Brain. 2006;129:12–90.
Camdessanché JP, Belzil VV, Jousserand G, Rouleau GA, 112. 
Créac’h C, Convers P, Antoine JC. Sensory and motor neu-
ronopathy in a patient with the A382P TDP-43 mutation. 
Orphanet J Rare Dis. 2011;6:4.
o’donnell JA, Emery Cl. Neurosyphilis: a current review. 113. 
Curr Infect Dis Rep. 2005;7:277–284.
logina I, Donaghy M. Diphtheritic polyneuropathy: a 114. 
clinical study and comparison with Guillain-Barre syn-
drome. J Neurol Neurosurg Psychiatry. 1999;67:433–438.
Harrington WJ Jr, Sheremata W, Hjelle B, Dube Dk, 115. 
Bradshaw P, foung Sk, Snodgrass S, Toedter G, Cabral 
l, Poiesz B. Spastic ataxia associated with human T-cell 
lymphotropic virus type II infection. Ann Neurol. 1993;33: 
411–414. 
Sheremata WA, Harrington WJ Jr, Bradshaw PA, foung 116. 
Sk, Raffanti SP, Berger JR, Snodgrass S, Resnick l, Poi-
esz BJ. Association of ‘(tropical) ataxic neuropathy’ with 
HTlV-II. Virus Res. 1993;29:71–77.
oluwole oS, onabolu Ao, link H, Rosling H. Persistence 117. 
of tropical ataxic neuropathy in a Nigerian community. 
J Neurol Neurosurg Psychiatry. 2000;69:96–101.
Joint Task force of the EfNS and the PNS. European 118. 
federation of Neurological Societies/Peripheral Nerve 
Society Guideline on management of paraproteinemic de-
myelinating neuropathies. Report of a Joint Task force of 
the European federation of Neurological Societies and the 
Peripheral Nerve Society—first revision. J Peripher Nerv 
Syst. 2010;15:185–195.
Van den Bergh Py, Hadden RD, Bouche P, Cornblath DR, 119. 
Hahn A, Illa I, koski Cl, leger JM, Nobile-orazio E, Pol-
lard J, Sommer C, van Doorn PA, van Schaik IN. European 
federation of Neurological Societies/Peripheral Nerve 
Society guideline on management of chronic inflamma-
tory demyelinating polyradiculoneuropathy: report of a 
joint task force of the European federation of Neurologi-
cal Societies and the Peripheral Nerve Society—first revi-
sion. Eur J Neurol. 2010;17:356–363.
Donofrio_R1_CH20_02-17-2012_273-288.indd           288                            Manila Typesetting Company                         02/17/2012  05:47PM
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
Q1: Please confirm if text corrections (changes to “and” and “or”) are as intended.
Q2:  Please clarify the groups being compared. Is “between antiamphiphysin, anti-CV2, paraneoplastic SNN, and 
sensorimotor neuropathy ans SClC, breast, colon, prostate, thymoma, and other cancers for the peripheral 
neuropathies”?
Q3: Please check this fragment, this is not a sentence.
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